The Native Antigen Company Introduces New Range of Influenza Antigens
Oxford, UK, 16 November 2022: The Native Antigen Company (part of
LGC Clinical Diagnostics), one of the world’s leading suppliers of
reagents that enables research into vaccines and diagnostics for
emerging and endemic infectious diseases, today announced the commercial
launch of its latest range of influenza antigens for the southern
hemisphere’s 2023 flu season. The latest influenza antigens will help
support development of vaccines and diagnostics as part of the ongoing
vaccine reformulation programme, helping to ensure public safety
throughout the annual flu season.
More info >> |